Navigation Links
Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
Date:4/20/2011

SAN FRANCISCO, April 20, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) ("the Company")and maintains its twelve month target price of $6.50. Ross Silver, Principal Analyst at Vista Partners stated, "According to the Company, Opexa's lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, is scheduled to advance into a pivotal Phase 3 clinical study in the U.S. in the second of half of 2011." Mr. Silver continued, "In clinical trials performed to date, Tovaxin® has compared favorably to already approved MS therapies, which are multi-billion dollar drugs. Of most significance in our opinion is Tovaxin® ranking ahead of both Copaxone® and Avonex® in Annualized Relapse Rate ("ARR"). ARR is possibly the most clinically relevant endpoint and is the single most important measure by which the FDA evaluates MS drugs for approval." Mr. Silver concluded, "Dendreon's Provenge®, the first FDA-approved autologous cellular immunotherapy which was recently approved by The Centers for Medicare and Medicaid Services for reimbursement of $93,000, has increased awareness and acceptance for this therapeutic approach."

To download a FREE copy of the Opexa Therapeutics, Inc. research report, please visit http://www.vistapglobal.com and complete the research form to gain access to the report.

About Vista Partners:

Vista Partners LLC, founded in 2005,  is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit the Vista Partners website at www.vistapglobal.com or click here.

Contact:
877.215.4813 or info@vistapglobal.com


'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
2. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
3. Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairss VistA Imaging System
4. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
5. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
6. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
7. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
8. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
9. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
10. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
11. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Research and Markets has announced ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ... ... technologies will rise from USD 20 Billion in 2015 to around ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... VANCOUVER , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) ... the Bloom Burton & Co. Healthcare Investor Conference 2017 at the ... Edward Wright , Chief Executive Officer of the Company is ... Company,s CFO, Richard Bear and the Chairman of the ... ...
Breaking Medicine Technology:
(Date:4/25/2017)... NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed ... treatment of acute or chronic problems, I focus on preventative care with all my patients ... you have any questions, always feel free to contact my office and my trained staff ...
(Date:4/25/2017)... ... 25, 2017 , ... Amendia, Inc., designer, developer, and manufacturer ... with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization dedicated ... complex spine deformity cases, particularly in children. , GSO’s focus is to provide ...
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point ... strategies to reduce waste, and support renewable energy. They believe this is a crucial ... to find solutions for health issues, and maintain that destroying the environment in the ...
(Date:4/24/2017)... Sacramento, Calif. (PRWEB) , ... April 24, 2017 , ... ... nearly $1.6 million in charitable dental services to 1,961 people during the April 22-23 ... services at no charge to Californians who experience barriers to care, CDA Cares educates ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... they are seeking public support to bring their novel lifesaving device for the ... device packed with medical-grade sensors, specially designed to read a child’s vital signs, ...
Breaking Medicine News(10 mins):